GlassScriptPhysician profile
Donna D Burroughs
NPI 1831213545
$3,706.17
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,027 · 2022: $1,511 · 2023: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $394.02 | 2021-2023 | |
| Lilly USA, LLC | $357.40 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $317.96 | 2021-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $305.39 | 2021-2023 | Wegovy, Tresiba, Ozempic |
| Insulet Corporation | $301.49 | 2021-2023 | Omnipod |
| Amgen INC. | $184.75 | 2021-2023 | Repatha, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $181.05 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $161.14 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $154.49 | 2021-2022 | |
| Dexcom, INC. | $149.40 | 2021-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $108.69 | 2021-2023 | |
| Medtronic, INC. | $104.03 | 2021-2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.74 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $85.57 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $76.64 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $68.70 | 2021-2022 | |
| Abbott Laboratories | $62.40 | 2021-2023 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $60.06 | 2021-2023 | Strensiq |
| Ascendis Pharma Endocrinology INC | $56.27 | 2023 | |
| Recordati_rare_diseases_inc. | $54.29 | 2021-2023 | Signifor Lar, Isturisa |
| Ibsa Pharma INC. | $52.58 | 2022 | |
| Antares Pharma, INC. | $52.25 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Becton, Dickinson and Company | $43.56 | 2021-2022 | |
| Clarus Therapeutics INC. | $43.15 | 2021 | |
| Amryt Pharma Holdings LTD | $38.72 | 2022-2023 | Myalept |
| Zealand Pharma US, INC. | $36.30 | 2021-2022 | |
| Esperion Therapeutics, INC. | $29.52 | 2021 | |
| Astellas Pharma US INC | $29.10 | 2023 | Veozah |
| Cequr Corporation | $26.49 | 2022-2023 | Cequr Simplicity |
| Nevro Corp. | $24.52 | 2022 | |
| Amneal Pharmaceuticals LLC | $22.32 | 2022 | |
| Mannkind Corporation | $17.85 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $15.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.